Avantor price target raised to $30 from $27 at Barclays

Barclays raised the firm’s price target on Avantor to $30 from $27 and keeps an Overweight rating on the shares. The analyst says Q1 is shaping up to be a rather inconsequential “do nothing” quarter for the life science tools and diagnostics space. The firm does not expect to get a lot of data one way or the other on many of the bull/bear debates. It believes investors continue to favor bioprocessing names broadly over instrument-focused companies.